A human rights NGO based in the Congolese capital Brazzzaville has denounced the suspension of antiretroviral (ARV) drug treatments for thousands of HIV/AIDS patients in Congo.
"As we speak, Congo is totally lacking ARVs. We’ve been to enquire at the Outpatient Treatment Centre [which supports patients]: It has no Atripla, Efavirenz or Nevirapine,” Pan African Association Thomas Sankara (APTS) chairman Germain Cephas Ewangui told IRIN.
"The situation could cause a rise in the number of deaths, the development of resistance [to ARVs administered later] and the recurrence and development of opportunistic infections. The situation is serious: we are facing very serious violations of human rights and particularly the right to life," said Ewangui.
"It is indeed a form of irresponsibility that we equate to an organized crime, requiring not only administrative sanctions, but also... prosecution because the situation is serious, intolerable and unacceptable," Ewangui added.
According to the Ministry of Health and Population, some 16,310 patients in Congo were receiving ARVs, while 38,500 are waiting to get them.
The ministry acknowledged that ARV treatment had stopped. "There was a malfunction. There was a break in the supply and distribution chain, but the situation is being corrected," said Executive Secretary of the National Council for the Fight against AIDS (CNLS) Marie-Francke Puruehnce.
"The situation should not lead to declarations and denunciations," said Puruehnce.
A consultant from the Ministry of Health, who requested anonymity, told IRIN: "Such failures sometimes happen once or twice a year. But they do not last long."
Officially Congo spends 2-5 billion CFA francs (US$4-10 million) a year on providing free treatment to HIV/AIDS patients.
According to the ministry, HIV prevalence fell from 4.2 percent in 2003 to 3.2 percent in 2011. The prevalence of pregnant women with HIV/AIDS fell from 3.4 percent in 2009 to 2.8 percent in 2012.
Congo, where per capita income in 2011 was estimated at $4,600, committed in 2001 to allocate 15 percent of the state budget to health, but it is currently earmarking only about 9 percent, according to the World Bank.
Interruption of ARV therapy risks patients developing resistance to the drugs and can hasten progress to AIDS and death.
This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions
Hundreds of thousands of readers trust The New Humanitarian each month for quality journalism that contributes to more effective, accountable, and inclusive ways to improve the lives of people affected by crises.
Our award-winning stories inform policymakers and humanitarians, demand accountability and transparency from those meant to help people in need, and provide a platform for conversation and discussion with and among affected and marginalised people.
We’re able to continue doing this thanks to the support of our donors and readers like you who believe in the power of independent journalism. These contributions help keep our journalism free and accessible to all.
Show your support as we build the future of news media by becoming a member of The New Humanitarian.